SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation about potential cannabis rescheduling, spurred by rumors of a Trump announcement and an upcoming Supreme Court case, igniting a flurry of activity. The community is buzzing with anticipation of federal policy changes and discussing potential short squeezes. Positive sentiment is fueled by analyst upgrades and developments in state-level cannabis programs.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's earnings and guidance beat is driving significant after-hours chatter, though some question if it's enough to justify the current valuation. Community members are closely watching the conference call for further insights, with some drawing parallels to recent market reactions to other AI-related stocks. Skepticism remains around the sustainability of AI partnerships and revenue, with some suggesting a potential pullback.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as traders react to a surprise CEO exit alongside a monster earnings report and upbeat guidance, with community members pointing to potential new leadership and significant buyback programs. Despite some concerns over tariffs and international expansion, bulls are optimistic about the company's potential for growth, while bears express concern about market saturation from competing brands.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending amid speculation about upcoming 48-week data and potential FDA meeting outcomes, with community chatter focused on whether the data will support a breakthrough therapy designation. Discussions also involve potential buyout scenarios and comparisons to competitors in the MASH/obesity space, while some traders express concern about trial results and management decisions. The stock's volatile price movement and high short interest add to the intense debate among bulls and bears.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian ($RIVN) is trending as investors await its Autonomy and AI Day, where the company is expected to showcase its self-driving technology and in-house AI software. Community discussions revolve around expectations for the event, potential advancements, and the long-term implications of Rivian's AI strategy. Recent trading activity indicates high options volume and volatility, with some skepticism balanced by bullish sentiment.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors digest recent earnings and revenue figures, with community chatter focusing on membership growth, online sales traction, and potential special dividends. Despite positive aspects, concerns about valuation, tariffs, and the company's legal actions are also part of the conversation. Overall, the community is assessing whether Costco can maintain its premium valuation amid changing economic conditions and shifting consumer behavior.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

$HOOD is trending due to recent news of slower trading volumes and mixed analyst opinions, causing a price dip. The community is debating whether to "buy the dip" or if the slowdown signals a concerning trend, while others are bullish due to expansion into Indonesia.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is trending amidst mixed sentiment following its recent earnings report and CEO commentary, particularly around the housing market and tariff impacts. While some investors appreciate the honesty, others are critical of the company's performance and leadership's communication, sparking debates about the company's future and valuation. Discussions also involve potential short squeezes, long-term growth strategies, and the impact of macroeconomic factors such as interest rates and tariffs on RH's luxury furniture business.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending as investors discuss the company's accelerated timeline for commercial production and a deal to supply rare earth materials, potentially positioning it as a key player in the domestic supply chain. Community members are weighing the impact of these developments against market volatility and the upcoming Russell 2000 inclusion, with some anticipating a significant price increase. Discussions also involve the stock's technical setup and the broader implications for the rare earth sector amid geopolitical tensions.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending amid an analyst upgrade from Cantor Fitzgerald, with a price target increase to $15, fueling bullish sentiment and community discussions about a potential short squeeze and future growth. Despite some skepticism and volatility, optimism persists around the company's AI technology and potential catalysts, including upcoming conference presentations and earnings reports. Community members are actively debating the stock's potential and the actions of short-sellers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer...

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire AUSTIN...

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1...

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Announces European Patent Office's Intent...

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...

&nbsp;1) Butterfly Network (NYSE: BFLY)<ul><li>Background: Butterfly Network is a digital health company pioneering accessible ultrasound technology through its handheld devices, with a mission to democratize high-quality imaging. The Butterfly iQ series has applications in multiple healthcare settings, enabling diagnostic imaging that is portable, affordable, and accessible.</li><li>The News: Butterfly Network recently partnered with HeartFocus to launch an AI-driven training app for cardiac ultrasound, compatible with Butterfly’s portable iQ devices. The app is designed to help healthcare practitioners acquire essential diagnostic skills, even in remote and underserved areas, boosting Butterfly’s appeal to health professionals globally.</li><li>What It Means: This partnership aligns with Butterfly’s vision of expanding ultrasound accessibility, particularly in resource-limited settings. By combining advanced AI-powered education with Butterfly’s handheld devices, the company positions itself as a leader in mobile diagnostics. As demand for accessible healthcare tech grows, Butterfly Network’s innovation could drive significant adoption and revenue growth.</li><li>Stock Reaction: Shares of BFLY rose 3.8%, with trading volume showing heightened interest following the announcement. Investors appear optimistic that AI integrations will boost device uptake, especially among hospitals and clinics focused on remote care.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_20_24_AM_903272e4bf.png" alt="Screenshot 2024-10-29 at 3.20.24 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;2) Gilat Satellite Networks (NASDAQ: GILT)<ul><li>Background: With over 35 years of experience, Gilat Satellite Networks specializes in satellite-based broadband communication solutions, catering to sectors like government, defense, and enterprise. Known for its high-quality and scalable communication systems, Gilat has a strong global reputation in satellite technology.</li><li>The News: Gilat was awarded a $4 million contract from the U.S. Department of Defense to supply DKET 3421 terminals, versatile communication hubs designed for field deployment. These terminals will enhance mission-critical communications, providing secure, mobile connectivity in challenging environments.</li><li>What It Means: This contract reinforces Gilat’s standing as a trusted defense partner, underscoring the value of its portable satellite solutions in national security contexts. Such government contracts bring stable revenue and validate Gilat’s reliability in high-stakes applications.</li><li>Stock Reaction: GILT shares rose 2.9% on above-average volume, reflecting investor confidence in Gilat’s steady pipeline of government contracts.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_07_AM_975e4948a4.png" alt="Screenshot 2024-10-29 at 3.21.07 AM.png"></li></ul>&nbsp;3) Power Nickel (TSXV: PNPN)<ul><li>Background: Power Nickel, a Canadian junior exploration company, focuses on nickel and other essential metals used in electric vehicle (EV) batteries. Its primary asset, the Nisk property in Quebec, has yielded high-grade nickel and copper, attracting attention within the green tech sector.</li><li>The News: Power Nickel announced promising drill results from the Lion Zone, with intersections showing high concentrations of copper, gold, and palladium. These results enhance the project’s profile, potentially making Power Nickel a key player in sustainable, North American-based battery metals.</li><li>What It Means: With demand for nickel and battery metals on the rise, Power Nickel’s findings position it well to meet the needs of EV manufacturers seeking local, reliable sources. The results are likely to attract both investment and strategic partnerships within the green energy sector.</li><li>Stock Reaction: PNPN shares fell 2.41%, with trading volume up almost 100% from average indicating growing investor enthusiasm for Power Nickel’s expansion potential.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_17_AM_62f6fd842f.png" alt="Screenshot 2024-10-29 at 3.21.17 AM.png"></li></ul>&nbsp;4) Genprex (NASDAQ: GNPX)<ul><li>Background: Genprex is a gene therapy company focused on cancer and diabetes treatments. Its flagship product, Reqorsa, aims to restore tumor-suppressor gene function in cancer patients, showing promise in treating resistant forms of lung cancer.</li><li>The News: Genprex presented positive preclinical data on Reqorsa, showcasing potential effectiveness against KRAS-resistant lung cancer, glioblastoma, and mesothelioma. This data, shared at an international symposium, underscores Reqorsa’s potential as a versatile cancer therapy.</li><li>What It Means: These findings reinforce Genprex’s pipeline credibility and could lay the groundwork for future clinical trials. If further studies replicate these results, Genprex may secure institutional investment as the therapy advances toward regulatory milestones.</li><li>Stock Reaction: GNPX shares surged 38.4% on higher-than-normal volume, as the announcement generated interest among investors.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_26_AM_dab873c609.png" alt="Screenshot 2024-10-29 at 3.21.26 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;5) Monte Rosa Therapeutics (NASDAQ: GLUE)<ul><li>Background: Monte Rosa Therapeutics is developing molecular glue degraders, which eliminate disease-causing proteins. This unique drug class has potential applications in autoimmune diseases, inflammation, and other conditions with few existing treatments.</li><li>The News: Monte Rosa announced a $150 million licensing agreement with Novartis to accelerate its VAV1-directed drug development program. The agreement provides Monte Rosa with significant financial backing to pursue its pipeline.</li><li>What It Means: Partnering with Novartis offers Monte Rosa access to substantial resources and validation for its innovative therapy approach. This collaboration could enhance Monte Rosa’s position within the biotech landscape, while boosting investor confidence.</li><li>Stock Reaction: GLUE shares jumped 93.9% as trading volume spiked, 27,000% reflecting market approval of the deal’s long-term growth potential.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_35_AM_fced9c05f9.png" alt="Screenshot 2024-10-29 at 3.21.35 AM.png"></li></ul>&nbsp;6) Atlas Lithium (NASDAQ: ATLX)<ul><li>Background: Atlas Lithium is a lithium exploration and development company working on the Neves project in Brazil’s “Lithium Valley.” With the global shift toward EVs and renewable energy storage, lithium is in high demand for battery production.</li><li>The News: Atlas secured regulatory permits to proceed with lithium extraction and processing at the Neves site. These approvals allow Atlas to develop a processing plant, positioning it to become a lithium supplier in the rapidly expanding EV battery market.</li><li>What It Means: This milestone accelerates Atlas’s journey to become a key player in the lithium supply chain. As EV adoption grows, Atlas’s Neves project may play a crucial role in meeting global lithium demand.</li><li>Stock Reaction: ATLX shares gained 24.7% on increased trading volume (5x), as investors anticipate the project’s potential impact on Atlas’s valuation.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_43_AM_6743660382.png" alt="Screenshot 2024-10-29 at 3.21.43 AM.png"></li></ul>&nbsp;7)Procept BioRobotics (NASDAQ: PRCT)<ul><li>Background: Procept BioRobotics specializes in robotic systems for urological procedures. Its AquaBeam Robotic System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), has shown significant market growth.</li><li>The News: Procept reported strong Q3 earnings, driven by increased AquaBeam sales and consumables. The company raised its revenue guidance, signaling robust demand and operational growth.</li><li>What It Means: Procept’s earnings beat highlights its competitive edge in surgical robotics, particularly in the high-demand market for BPH treatment. The raised guidance reflects Procept’s confidence in continued market penetration and long-term revenue potential.</li><li>Stock Reaction: PRCT shares rose 32.3% on significant volume (6x), with investors responding positively to the improved financial outlook.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_22_05_AM_0dfbb455f8.png" alt="Screenshot 2024-10-29 at 3.22.05 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion on the WVC Facebook Investor Group</a><a target="_blank" rel="noopener noreferrer nofollow" href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;&nbsp;Have a Stock Tip or New Story Suggestion? Email us at: Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Small and Micro-Cap Movers: Key News, Market Reactions, and Insider Chatter

Equity

Today’s most impactful small-cap stock updates, with exclusive rumors, insights, and analysis from StockTwits

Walt Disney Co. (<a class="mention" data-mention="$DIS" data-symbol-id="DIS" href="https://stocktwits.com/symbol/DIS" target="_blank">$DIS</a>)<figure class="image"><a href="https://stocktwits.com/symbol/DIS"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DIS_sentiment_and_message_volume_Oct_21_2024_7dcf3c3bd2.png" alt="DIS sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>DIS sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>Sentiment on Stocktwits for Walt Disney Co. turned ‘bullish’ (69/100) early Monday before the market opened, compared to a ‘bearish’ sentiment just a day earlier. Disney’s stock has risen nearly 3.5% over the past week. Recent news driving the stock includes Disney’s announcement to pilot a new fast-pass option for rides at its U.S. theme parks, with peak pricing as high as $449. Additionally, Piper Sandler initiated coverage with a ‘Neutral’ rating and a $95 price target. The analyst noted limited upside in the next few quarters due to moderation in Disney’s experiences segment, but remains optimistic about Disney’s broader assets and recent film successes.VSee Health Inc. (<a class="mention" data-mention="$VSEE" data-symbol-id="VSEE" href="https://stocktwits.com/symbol/VSEE" target="_blank">$VSEE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/VSEE"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GNPX_sentiment_and_message_volume_Oct_21_2024_3a5b20d8d3.png" alt="GNPX sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>VSEE sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>VSee Health scored an ‘extremely bullish’ (97/100) sentiment on Stocktwits pre-market Monday, following a nearly 36% stock gain over the past week. The surge was driven by the announcement of a telehealth initiative in collaboration with Kwajalein Atoll Local Government (KALGOV) and Kwajalein Atoll Sustainability Laboratory (KASL). The project leverages SpaceX’s Starlink technology and VSee’s telemedicine platform to provide virtual healthcare consultations aboard a boat ambulance, aimed at improving access for Marshallese veterans and residents of the Kwajalein Atoll.Genprex, Inc. (<a class="mention" data-mention="$GNPX" data-symbol-id="GNPX" href="https://stocktwits.com/symbol/GNPX" target="_blank">$GNPX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GNPX"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VSEE_sentiment_and_message_volume_Oct_21_2024_70aa2e5cb4.png" alt="VSEE sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>GNPX sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>Gene therapy company Genprex saw its Stocktwits sentiment hit ‘extremely bullish’ pre-market Monday, after a week of impressive gains over 28%. The optimism followed the company’s announcement that it had advanced to the highest dose group in its Acclaim-3 small cell lung cancer trial for Reqorsa Gene Therapy with Tecentriq, after receiving approval from a safety review committee. &nbsp;

Walt Disney, VSee Health, Genprex: Retail Most Bullish On These 3 Stocks Pre-Market

Disney’s fast-pass pilot, VSee Health’s telehealth initiative, and Genprex’s gene therapy trial progress are driving strong interest

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Genprex Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$3.24
Prev Close	$3.33
Open	$3.32
Dividend Yield	0.00%
50-Day Moving Average	$7.57
Beta	1.24
Avg. Volume	298,170.16
PE Ratio	-0.07

52-Week High	$63.00
52-Week Low	$2.61
Market Capitalization	$7.72M
EPS (Annual)	-$266.95
Price to Book	4.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GNPX
Genprex Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GNPX News

GNPXGenprex Inc